Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Wei, Andrew H. [1 ,2 ,3 ]
Seymour, John F. [1 ,2 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
基金：
英国医学研究理事会;
关键词：
myelodysplastic syndromes; Hypomethylating agents; lenalidomide; CONVENTIONAL CARE REGIMENS; AZACITIDINE; LENALIDOMIDE; CLASSIFICATION; COMBINATION;
D O I：
10.1111/bjh.18240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18193.
引用
下载
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [21] Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    O'Keefe, Christine
    List, Alan F.
    Paulic, Katarina
    Afable, Manuel, II
    Englehaupt, Ricki
    Maciejewski, Jaroslaw P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 102 - 103
  • [22] Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Hill, Kala
    Salimi, Tehseen
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] AzacitidineA Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Gillian M. Keating
    Drugs, 2009, 69 : 2501 - 2518
  • [24] Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.
    Mufti, G. J.
    Herman, J. G.
    Gore, S.
    Seymour, J. F.
    Santini, V.
    Hagemeijer, A. M.
    Skikne, B.
    MacBeth, K. J.
    Lucy, L. M.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Tiu, Ramon V.
    Komrokji, Rami
    Lancet, Jeffrey
    Advani, Anjali S.
    Afable, Manuel
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Tabarroki, Ali
    Visconte, Valeria
    Makishima, Hideki
    Jerez, Andres
    Paquette, Ronald
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2012, 120 (25) : 4945 - 4951
  • [26] CHARACTERIZATION OF MRNA EXPRESSION OF GENES INVOLVED IN MEGAKARYOCYTE DEVELOPMENT IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Fabiani, E.
    Falconi, G.
    Criscuolo, M.
    Fianchi, L.
    Picardi, A.
    Buccisano, F.
    Maurillo, L.
    Lo Coco, F.
    Voso, M. T.
    LEUKEMIA RESEARCH, 2017, 55 : S99 - S99
  • [27] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [28] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    Sanz, G.
    LEUKEMIA, 2016, 30 (03) : 740 - 741
  • [29] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    Zeidan, A. M.
    Sekeres, M. A.
    Garcia-Manero, G.
    Steensma, D. P.
    Zell, K.
    Barnard, J.
    Ali, N. A.
    Zimmerman, C.
    Roboz, G.
    DeZern, A.
    Nazha, A.
    Jabbour, E.
    Kantarjian, H.
    Gore, S. D.
    Maciejewski, J. P.
    List, A.
    Komrokji, R.
    LEUKEMIA, 2016, 30 (03) : 649 - 657
  • [30] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    A M Zeidan
    M A Sekeres
    G Garcia-Manero
    D P Steensma
    K Zell
    J Barnard
    N A Ali
    C Zimmerman
    G Roboz
    A DeZern
    A Nazha
    E Jabbour
    H Kantarjian
    S D Gore
    J P Maciejewski
    A List
    R Komrokji
    Leukemia, 2016, 30 : 649 - 657
12345